Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.

Journal: European journal of cancer (Oxford, England : 1990)
PMID:

Abstract

PURPOSE: Ovarian cancer patients with a Homologous Recombination Deficiency (HRD) often benefit from polyadenosine diphosphate-ribose polymerase (PARP) inhibitor maintenance therapy after response to platinum-based chemotherapy. HR status is currently analyzed via complex molecular tests. Predicting benefit from PARP inhibitors directly on histological whole slide images (WSIs) could be a fast and cheap alternative.

Authors

  • Frederik Marmé
    Department of Obstetrics and Gynaecology, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany.
  • Eva I Krieghoff-Henning
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
  • Lennard Kiehl
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
  • Christoph Wies
    Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jan Hauke
    Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
  • Eric Hahnen
    Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
  • Philipp Harter
    Ev. Kliniken Essen Mitte, Essen, and Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Studiengruppe, Germany.
  • Philip C Schouten
    Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Tobias Brodkorb
    Department of Obstetrics and Gynaecology, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany.
  • Mohamad Kayali
    Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
  • Florian Heitz
    Ev. Kliniken Essen Mitte, Essen, and Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Studiengruppe, Germany.
  • Claudio Zamagni
    IRCCS Azienda Ospedaliero-universitaria di Bologna, and MITO, Italy.
  • Antonio González-Martin
    Clinica Universidad de Navarra, Madrid, and GEICO, Spain.
  • Isabelle Treilleux
    Centre Léon Bérard, Lyon, and GINECO, France.
  • Stefan Kommoss
    Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • Katharina Prieske
    Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Timo Gaiser
    Institute of Pathology, University Medical Center Mannheim, Mannheim, Germany.
  • Stefan Fröhling
    National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
  • Isabelle Ray-Coquard
    Centre Léon Bérard, Lyon, and GINECO, France.
  • Eric Pujade-Lauraine
    Association de Recherche sur les CAncers dont GYnécologiques (ARCAGY)-GINECO, Paris, France.
  • Titus J Brinker
    National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.